Goli Pharmaceutical-B (01672) increased share repurchase capital from a maximum of HK$300 million to a maximum of HK$500 million

According to the Zhitong Finance App, Goli Pharmaceutical-B (01672) announced that the board of directors believes that the company's current stock price is undervalued and decided to increase the share repurchase capital from a maximum of HK$300 million to a maximum of HK$500 million on December 15, 2025.

According to the announcement, the increase in repurchase capital is a major achievement considering the company's important milestones, including but not limited to: (1) the US 13-week phase II study of the Geli oral small molecule GLP-1 agonist ASC30 in obese or overweight subjects showed a weight loss of up to 7.7% after placebo correction and better gastrointestinal tolerability; (2) the lipose-targeted thyroid receptor (beta THRβ) selective small molecule agonist ASC47 was effective in reducing monobese weight compared to simeglutide in obese subjects Relative increase of up to 56.2% ;( 3 ) It is expected to become the best oral small molecule interleukin-17 (IL-17) inhibitor with positive top-line results in the ASC50 US Phase I study; and (4) the marketing application for a new drug with similar pioneering fatty acid synthase (FASN) inhibitor dinifastat (ASC40) to treat acne was accepted by the China Drug Administration.

The company's current financial position is sound. The Board of Directors believes that the current transaction price of the shares does not reflect their intrinsic value. The Board believes that the updated proposed share buyback will enhance the value of shares, thereby increasing shareholder returns. Furthermore, the Board believes that the updated proposed share repurchase reflects the company's full confidence in its long-term business prospects and the company's growth potential, and will ultimately benefit the company and the best interests of the company and shareholders as a whole.

On December 15, 2025, the company has used approximately HK$54.28 million (not including expenses) to repurchase 4.586 million shares of common stock in accordance with the repurchase authorization since October 2, 2025.